Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349887 | PMC |
| http://dx.doi.org/10.5694/mja2.51662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Learning from inborn errors of immunity and secondary immune deficiencies about vaccine immunogenicity, efficacy and safety.
Clin Exp Immunol
September 2025
Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, B15 2TT.
Since its discovery in the late 18th Century, the role of vaccination in preventing death and disease has expanded across many infectious diseases and cancer. Key to our understanding of vaccine immunogenicity and efficacy is knowledge of the immune system itself. Inborn Errors of Immunity (IEI) represent a heterogeneous group of disorders characterised by impaired function of the immune system.
View Article and Find Full Text PDFImproving vaccine communication to the often-overlooked young adult population: A qualitative study of 20-29 year olds in British Columbia, Canada.
Hum Vaccin Immunother
December 2025
Vaccine Evaluation Center, British Columbia Children's Hospital Research Institute, Vancouver, Canada.
Young adults in their 20s have shown slower uptake of COVID-19 vaccines relative to older adults, potentially endangering themselves and their communities. Despite this, little vaccine communication has specifically targeted this age group. This study explored why "20-somethings" in British Columbia (BC), Canada delayed COVID-19 vaccination, and how to better encourage their vaccine uptake.
View Article and Find Full Text PDFCharacterization of Early Viral Populations in Infants Acquiring HIV Through Perinatal and Breastmilk Transmission: A Review of what is Currently Known and the Gaps that Need to be Addressed to Guide Passive HIV Immunization of Breastfeeding Infants.
Curr HIV Res
September 2025
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
Newborns represent only 1% of the population. Yet, HIV vertical transmissions represent 10% of all new infections globally, even though antiretroviral therapy (ART) has been shown to reduce the risk of vertical transmission to less than 2%. While vaccines still represent the most efficient and cost-effective intervention to eradicate new infections, HIV immunogens that can effectively elicit broad-spectrum protection are still at least a decade away.
View Article and Find Full Text PDFNeutralizing monoclonal antibodies against dengue virus: a scoping review of preclinical and clinical development.
Virology
September 2025
Department of Medicine, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).
View Article and Find Full Text PDFCorrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age" [Vaccine 62 (2025) 127456].
Vaccine
September 2025
Merck & Co., Inc., Rahway, NJ, USA. Electronic address: